Atezolizumab Plus Bevacizumab in Advanced HCC: Efficacy in NASH-Specific Etiology. Llovet JM, Heikenwalder M. Gastroenterology 2023;165:1308-1310.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Llovet JM, Heikenwalder M. Atezolizumab Plus Bevacizumab in Advanced HCC: Efficacy in NASH-Specific Etiology. Gastroenterology 2023;165:1308-1310.
PMID: 37116832